Marco Ventin
@MVentinMD
Followers
241
Following
906
Media
12
Statuses
138
General Surgery @UCIrvineSurgery | Postdoc @CedarsSinai @MGHSurgery Ferrone Lab | Interested in HPB Surgery, Cancer Immunology & Immunotherapy
Los Angeles, CA
Joined January 2021
CARES-009 raises the bar for resectable HCC 🧬🩸 Phase 3 CARES-009 trial tested perioperative camrelizumab (PD-1) + rivoceranib (VEGFR + PD-1 combo) vs upfront surgery in resectable intermediate/high-risk HCC (CNLC Ib–IIIa). 🧠 Design: 2 cycles neoadjuvant → resection → ≥6
2
14
42
📢 Small NF PanNETs can/should be observed #ASPEN🏔️ @spartelli #ESMO25 👥Prospective multi-centre cohort 1️⃣0️⃣0️⃣0️⃣ PanNETs <2cm An image 🏞️ is worth 1000 words👇🏻 For resection: 😳NNT 276 ⚠️NNH 6 ✅No difference in OS surgery vs active surveillance 👏Congrats on landmark work!
1
20
63
🇪🇨✨ Incredible week in Ecuador! Our @BIDMCTransplant @Harvard team joined an @AHPBA -supported outreach mission in Quito — performing four live surgeries, including the first robotic major liver cancer resections and the first robotic living kidney donor surgery ever performed
2
7
56
Happening tomorrow! Join the CGSO Videoconference: Pancreas, on Wednesday, October 8, at 5:30 PM CST. Don’t miss the two live case presentations by CGSO Fellows Dr. Anup Parikh and Dr. James Luo, with guest expert Dr. Peter Allen. Register now: https://t.co/8u9nkwMBQ9
0
2
14
⁉️What are the top HPB surgical oncology studies of 2025 so far? Help the @socsurgonc HPB disease site working group find the top 10 studies to review for HPB 2025 wrapped What changed your practice? What advanced the field? Tell us 👇🏻
7
27
91
What is your anticoagulation practice 💉 after portal vein resection in pancreas surgery ?! 🧑🧑🧒🧒 1k pts / 90 days thrombosis 7% 🔮 Predictors resection type / graft material 🩸 Therapeutic anticoagulation 📉 early thrombosis but 👎 at 90 days https://t.co/16BWrpyt2Q
0
20
78
First-line atezo/bev vs. durva/treme in pts w/ advanced HCC. 452 pt retrospective study showing no OS difference, 14 mos vs. 14.6 mos. My apologies for the poor quality OS graph. https://t.co/potNGPTmCK
2
9
50
📌 Most viewed this week from JAMA Oncology: Glucagon-like peptide-1 receptor agonists (#GLP1s) are associated with a reduced overall #cancer risk in adults with #obesity, lowering the risk for endometrial, ovarian, and meningioma cancers. https://t.co/bzpYPPadmp
1
5
21
New study: Glisson’s capsule invasion as a risk factor of multifocal intrahepatic recurrence after hepatectomy for HCC. @SICOBoard @UpdatesSurgery @uniud
https://t.co/hoRgu9tTu2
0
0
3
New article by @GCattaneoPhD describing the Molecular basis for targeting TBK1 in CAR-T cell therapies for cancer @CSCancerCenter @MGHCancerCenter
tandfonline.com
Published in Expert Opinion on Therapeutic Targets (Vol. 29, No. 8, 2025)
0
0
1
We analyzed long term outcomes of cystic vs solid PanNETs. Low LN met and recurrence rate, with favourable survival for cystic PanNETs regardless of tumor size (</> 3 cm) support LN/parenchyma sparing operations, and observation in high risk surgical patients. @AnnalsofSurgery
1
5
26
Full article: Mature tertiary lymphoid structures linked to HPV status and anti-PD-1 based chemoimmunotherapy response in head and neck squamous cell carcinoma
tandfonline.com
Mature tertiary lymphoid structures (TLSs) are immune aggregates associated with immune checkpoint blockade (ICB) responses in various cancers, yet their role in chemoimmunotherapy response in head...
0
0
0
Does TXA reduce blood transfusion within 7d after hepatectomy? The HeLiX Randomized Clinical Trial | Bleeding and Transfusion | JAMA | JAMA Network
jamanetwork.com
This randomized clinical trial assesses the effect of tranexamic acid vs placebo on the need for blood transfusion among patients undergoing cancer-related liver resection.
0
0
1
Please join us in congratulating Dr. Alexandra Gangi as our new Division Director of Surgical Oncology in the Jim and Eleanor Randall Department of Surgery! 🎉👏👏👏 @AGangiMD
@CFerroneMD
@CSCancerCenter
22
20
119
If you’re a GI/HPB surgeon/oncologist who couldn’t make it to @ASCO 2025 & trying to scour for its ongoings online like I have been, here’s the 2 trials you’d probably be interested in with a concise breakdown: MATTERHORN, & CASSANDRA! (Also tagging ppl who are smarter than me)
5
29
137
Nonoperative Management of Mismatch Repair–Deficient Tumors | New England Journal of Medicine
nejm.org
Among patients with mismatch repair–deficient (dMMR), locally advanced rectal cancer, neoadjuvant checkpoint blockade eliminated the need for surgery in a high proportion of patients. Whether this ...
0
0
3
Congratulations to Dr. Xinhui Wang who has received a prestigious 4-year grant from the Department of Defense for her research project: “Development of Personalized Cancer Vaccines Targeting Tumor Heterogeneity and Reprogramming the Cold Tumor Microenvironment in Kidney Cancer.”
0
5
17
🚨PSA: the ALLIANCE A021806 for neoadjuvant vs adjuvant chemo in pancreas cancer is 4️⃣0️⃣ patients short of completing accrual Answer Dr Ferrone’s call: if each centre enrols 1️⃣ patient, enrolment will be complete! Lets do it! 💪
0
14
37
What about PNETs? #Pommier principles for resection of PNETs liver metastases at #AHPBA2025 To bookmark 🔖👇🏻
1
25
82